A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.

Autor:	Torres S; Molecular Oncology Laboratory, General University Hospital Research Foundation , Valencia, Spain.; CIBERONC , Madrid, Spain.; Mixed Unit TRIAL CIPF-FIHGUV , Valencia, Spain., González Á; Molecular Oncology Laboratory, General University Hospital Research Foundation , Valencia, Spain., Cunquero Tomas AJ; Medical Oncology Department, General University Hospital of Valencia , Valencia, Spain., Calabuig Fariñas S; Molecular Oncology Laboratory, General University Hospital Research Foundation , Valencia, Spain.; CIBERONC , Madrid, Spain.; Mixed Unit TRIAL CIPF-FIHGUV , Valencia, Spain.; Department of Pathology, Universitat de València , Valencia, Spain., Ferrero M; Molecular Oncology Laboratory, General University Hospital Research Foundation , Valencia, Spain., Mirda D; George Washington University School of Medicine and Health Sciences , Washington, DC, USA., Sirera R; CIBERONC , Madrid, Spain.; Mixed Unit TRIAL CIPF-FIHGUV , Valencia, Spain.; Department of Biotechnology, Universitat Politècnica de València , Valencia, Spain., Jantus-Lewintre E; Molecular Oncology Laboratory, General University Hospital Research Foundation , Valencia, Spain.; CIBERONC , Madrid, Spain.; Mixed Unit TRIAL CIPF-FIHGUV , Valencia, Spain.; Department of Biotechnology, Universitat Politècnica de València , Valencia, Spain., Camps C; Molecular Oncology Laboratory, General University Hospital Research Foundation , Valencia, Spain.; CIBERONC , Madrid, Spain.; Mixed Unit TRIAL CIPF-FIHGUV , Valencia, Spain.; Medical Oncology Department, General University Hospital of Valencia , Valencia, Spain.; Department of Medicine, Universitat de València , Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Expert review of molecular diagnostics [Expert Rev Mol Diagn] 2020 Jun; Vol. 20 (6), pp. 575-582. Date of Electronic Publication: 2020 Feb 20.
DOI:	10.1080/14737159.2020.1724094
Abstrakt:	Introduction: Among non-small cell lung cancer (NSCLC) patients, there is one molecularly defined subgroup harboring activating mutations in the epidermal growth factor receptor gene ( EGFR ), which results in constitutive activation of its intrinsic kinase activity. Consistent data have demonstrated that these patients have a better outcome when treated with specific tyrosine-kinase inhibitors (EGFR-TKIs). Therefore, analysis of EGFR mutational status for treatment guidance is mandatory in this context. Areas Covered: Herein we review the clinical development and technical features of cobas® EGFR Mutation Test v2 as a companion diagnostic test (CDx) for therapy with EGFR-TKIs, such as gefitinib, in advanced NSCLC. We also discuss the pros and cons of the current version of the CDx and its performance in both tissue and plasma samples. Expert Opinion: The RT-PCR based cobas® EGFR Mutation Test v2 is a reliable and rapid solution for EGFR mutational status assessment at the time of diagnosis in advanced NSCLC that allows eligibility of patients for EGFR-TKI treatment. This test determines EGFR mutations with acceptable sensitivity in tissue or plasma samples. Pre-analytical considerations like tumor cell content, tumor burden or location of metastasis should be considered to better interpret results in the clinical contexture.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu